



The Nifty ended 1.81% down at 10,607.35. It opened on a negative note and continued declining towards ending the session on a bearish trajectory. Finishing off the day below 10,720 brightens the possibility of further lows. Hence, staying cautious on rise is advised. Downside supports are placed around 10,530 and 10,470. 200 EMA is placed around 10,530 on daily chart.

On the Nifty hourly chart; breakdown in RSI took its toll as suggested several times before. Hence staying cautious on rise is advised. Downside supports are placed around 10,530 and 10,470.

Nifty patterns on multiple time frames suggest; ending the day in deep red is a concern, which suggests further down fall in the price range 10,530-10,470 is likely.

Nifty Crucial Supports & Resistances-
Supports- 10530, 10470 Resistances- 10720, 10760

Open positional calls-

T+15 Investment Buy-
|Cash Segment| Accumulate DCB on dips around @ 82-80, TGT- 100, SL- closing below 70

T+7 Positional Sell-
|Futures Segment| LUPIN Fut @ 882-885, TGT- 825, SL- above 915

T+7 Positional Sell-
|Futures Segment| TATA STEEL Fut @ 337-339, TGT- 309, SL- above 354

T+7 Positional Sell-
|Futures Segment| BEL Fut @ 101-102, TGT- 92, SL- above 107

T+15 Positional Buy-
|Cash Segment| Accumulate GLENMARK (CMP - 430.00) on dips around @ 425-420, TGT- 480, SL- closing below 390

BTST Positional Buy-
|Cash Segment| COLPAL (CMP- 1432.00) on dips around @ 1430-1425, TGT- 1465, SL- closing below 1405

Key Contents	Page No.
Result Analysis	4
Domestic News	5

Nifty Intraday Chart



Market in Retrospect

Indian equity markets has their biggest single-day drop since early-June, tracking weakness in Asian peers and sustained selling among largecap financial names.

The NSE Nifty 50 index ended 1.79% lower, ending at 10,609. The broader markets represented by the NIFTY 500 Index ended 1.59% lower, ending at 8693.35. NIFTY Pharma was the only top gainer, gaining by 0.48%. NIFTY Bank was the top loser, losing by 3.16%.

Dr. Reddy's was the top gainer, gaining by 2.14%, followed by Titan and Bharti Airtel, which gained by 0.77% & 0.43% respectively. Indusind Bank was the top loser, losing by 5.35%, followed by Axis Bank and Zee Enterprise, which fell by 5.08% & 4.29% respectively.

The Advance: Decline ratio stood at 481:1368

Market Turnover (In Crore) 14-07-2020

Name	Last	Previous
NSE Cash	54108.88	52354.62
NSE F&O	1510278.71	1167812.51
BSE Cash	3,092.97	3,193.10
BSE F&O	37.78	17.87

FII Derivatives Flow (In Crore) 13-07-2020*

Instrument	Purchase	Sale	Net
Index Future	3644.00	4142.30	498.3
Index Option	213161.66	212826.67	334.99
Stock Future	12424.94	13254.56	829.62
Stock Option	4242.33	4413.04	170.71

Institutional Flow (In Crore) 13-07-2020*

Institution	Purchase	Sale	Net
FII	3730.71	3508.95	221.76
DII	2803.89	4289.48	1485.59

*Data not updated till 5:55PM

NIFTY Top Gainers

Name	%1D	%5D	Day Vol	Avg 5 Day Vol
Dr. Reddy'S	2.14	4.18	1208945	851158
Titan	0.77	4.18	3642982	3569928
Bharti Airtel	0.43	3.91	32329098	12004060

NIFTY Top Losers

Name	%1D	%5D	Day Vol	Avg 5 Day Vol
Maruti Suzuki India	3.63	7.31	1602939	1250257
Eicher Motors	4.09	5.42	247507	251190
Zee Enterprise	4.29	7.76	15353973	20537400
Axis Bank	5.08	6.63	25686686	32007330
Indusind Bank	5.35	2.95	22221590	38816220

Bulk and Block Deals

<https://www.nseindia.com/products/content/equities/equities/bulk.htm>
<http://www.bseindia.com/markets/equity/EQReports/BulknBlockDeals.aspx>

Sensex Intraday Chart



Market in Detailed (Updated after 4:00 PM)

Indian Indices

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Sensex	36033.06	660.63	1.80	1.75	6.67	17.41	6.98
Nifty	10607.35	195.35	1.81	1.78	6.36	17.94	8.18
BSE M Cap	13276.60	127.14	0.95	1.92	5.37	17.82	8.78
BSE S Cap	12665.18	119.01	0.93	1.36	6.92	23.61	8.07
Nifty MC 100	15052.35	164.80	1.08	2.03	4.97	21.63	12.21
BSE Auto	15661.29	389.61	2.43	4.11	5.47	26.84	9.32
BSE Capgoods	12792.72	230.82	1.77	4.22	1.65	10.06	31.42
BSE FMCG	11421.97	105.46	0.91	1.33	4.92	6.69	1.80
BSE Metal	7442.26	190.19	2.49	1.81	4.55	18.27	29.39
BSE Oil&Gas	12827.90	104.10	0.80	0.17	2.38	17.37	8.95
BSE Healthcare	16655.59	1.82	0.01	2.30	3.26	12.76	28.88
BSE Power	1516.86	42.81	2.74	5.90	1.77	5.79	24.90
BSE Realty	1571.40	23.72	1.49	3.79	0.97	15.95	27.37
BSE ConsDur	20555.89	39.94	0.19	3.28	0.54	2.37	11.36
BSE Bank	24230.15	765.07	3.06	5.47	3.11	8.10	29.59
BSE IT	15741.34	254.88	1.59	1.56	9.53	24.32	4.23

Bond Markets

Name	Yield	Net Chng	%1D	%5D	%1M	%3M	%1Y
US	0.63	0.01	1.60	1.78	10.68	16.45	70.39
UK	0.16	0.02	12.90	10.00	22.12	52.49	80.60
Brazil	4.82	0.02	0.45	0.38	3.98	18.33	6.40
Japan	0.03	0.01	17.50	28.26	153.85	10.00	128.95
Australia	0.91	0.01	1.00	2.83	0.11	1.73	36.72
India	5.83	0.04	0.67	0.90	0.48	10.32	10.22
Switzerland	0.42	0.02	3.98	14.84	5.86	25.53	15.39
Germany	0.42	0.00	0.96	1.87	4.10	11.67	100.48

Currency

Name	Rate	Net Chng	%1D	%5D	%1M	%3M	%1Y
INR	75.43	0.24	0.32	0.65	0.80	1.12	9.13
USD Index	96.50	0.03	0.03	0.40	0.84	2.42	0.32
YUAN	7.02	0.02	0.28	0.05	1.05	0.49	1.99
GBP	1.25	0.00	0.26	0.16	0.66	0.80	0.05
EUR	1.14	0.00	0.21	0.83	0.40	3.53	0.98
YEN	107.39	0.10	0.09	0.12	0.06	0.16	0.48

Freight

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Baltic Dry	1792.00	18.00	0.99	8.38	94.15	163.92	3.91
Baltic Dirty	499.00	1.00	0.20	2.46	9.44	54.96	20.54
SG Dubai HY	0.31	0.14	31.11	58.67	162.00	65.93	95.62

Global Indices

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Dow Jones	26085.80	10.50	0.04	0.77	1.88	8.92	4.56
Nasdaq	10390.84	226.60	2.13	0.41	8.36	22.02	26.04
S&P 500	3155.22	29.82	0.94	0.77	3.75	10.86	4.69
FTSE100	6147.78	27.78	0.45	0.67	0.71	6.17	18.09
CAC40	4963.81	90.22	1.78	1.54	2.62	9.77	10.89
DAX	12598.73	198.63	1.55	0.12	5.46	17.81	2.26
Mexico IPC	36389.39	76.07	0.21	3.95	3.42	4.73	14.67
Brazil Bovespa	98697.10	1334.74	1.33	0.24	6.36	23.50	5.01
Russian RTS	1202.43	32.27	2.61	3.65	2.90	6.09	13.38
Japan Nikkei	22587.01	197.73	0.87	0.12	1.26	15.01	4.16
Hang Seng	25477.89	294.23	1.14	1.92	4.84	4.27	10.51
Taiwan Index	12209.01	2.55	0.02	0.96	6.82	18.16	12.79
Shanghai Comp	3414.62	28.67	0.83	2.07	16.95	20.77	16.52
KOSPI	2183.61	2.45	0.11	0.90	2.41	17.58	4.65
Malaysia KLCI	1598.75	7.68	0.48	2.04	3.41	16.56	4.23
Jakarta Comp	5079.12	14.68	0.29	1.85	4.07	7.92	20.31
Philippine SE	6172.81	0.24	0.00	1.51	4.69	6.78	24.18
Thai Exch	1341.07	1.30	0.10	2.34	3.00	6.74	22.55

Indian Indices

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
NYMEX Crude	39.75	0.36	0.90	2.17	9.60	97.61	34.00
BRENT Crude	42.44	0.29	0.68	1.51	8.85	13.78	33.19
Natural Gas	1.72	0.02	1.04	8.26	5.18	18.24	32.19

LME

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Gold(\$/Ounce)	1793.49	8.37	0.46	0.03	3.68	3.90	26.74
Silver(\$/Ounce)	18.91	0.15	0.81	3.55	8.17	20.12	24.32
Aluminium	1656.50	2.58	0.16	3.45	6.13	14.99	8.09
Copper	6580.00	161.45	2.52	7.25	14.21	31.78	10.98
Zinc	2253.75	70.25	3.22	9.86	14.62	19.45	7.94
Lead	1868.00	26.05	1.41	4.77	7.32	9.69	5.37

Agro Commodities

Name	Price	Net Chng	%1D	%5D	%1M	%3M	%1Y
Coffee	98.25	0.40	0.41	2.04	1.29	17.82	18.23
Cotton	62.69	0.66	1.04	0.52	6.20	13.30	4.38
Sugar	11.46	0.12	1.04	5.91	4.82	9.25	16.04
Wheat	530.25	5.50	1.05	7.07	4.43	4.42	5.19
Soybean	878.75	3.50	0.40	2.63	0.11	1.53	9.03

Mindtree

IT company, Mindtree, posted a 129.8 per cent year-on-year (YoY) growth in its consolidated net profit at INR213 crore for the quarter ended June 2020 (Q1FY20-21). On a sequential basis, the numbers grew 3.3 per cent. The company's revenue came in at INR1,908.8 crore, up 4.1 per cent YoY and down 6.9 per cent QoQ. In US dollar terms, revenue stood at \$253.2 million, down 4.1 per cent YoY and 9 per cent QoQ. Net profit came in at \$28.3 million, up 0.1 per cent QoQ and 111.7 per cent YoY. We closed the quarter with a healthy order book of \$391 million despite the global headwinds due to Covid-19 pandemic. Our unwavering focus on operational efficiencies has helped us to post a healthy EBITDA of 18.2 per cent. ICICI Securities had expected Mindtree's revenue in the US dollar terms to decline 7.5 per cent quarter-on-quarter (QoQ). In rupee terms, revenues were expected to decline 4.8 per cent QoQ to INR1,952 crore. On a year-on-year (YoY) basis, the numbers were seen growing 6.4 per cent. Net profit or profit after tax (PAT) was expected to stay flat at INR206.3 crore on a sequential basis. On a year-on-year basis, the profit was seen surging 122.5 per cent.

Wipro

Wipro reported its consolidated net profit for the June quarter was flat at INR2,390 crore as against INR2,388 crore in the year-ago period. The company's consolidated revenue rose marginally to INR14,913 crore as compared to INR14,716 crore in June 2019. Wipro's consolidated IT services revenue during the quarter also rose marginally to INR14,596 crore versus INR14,351 crore in year-ago period. The company's IT services EBIT margin improved to 19.1% as against 17.6% in the previous quarter and 18.4% in June 2019. Total income of Wipro was almost flat at INR15,571.4 crore in the April-June quarter compared to INR15,566.6 crore in the same quarter of the last financial year. The company on its IT services segment added 42 new customers in June quarter and that the IT services segment had a total headcount of 181,804 at the end of June.

Khadim India

Net loss of Khadim India reported to INR19.88 crore in the quarter ended March 2020 as against net profit of INR1.20 crore during the previous quarter ended March 2019. Sales declined 23.44% to INR158.22 crore in the quarter ended March 2020 as against INR206.67 crore during the previous quarter ended March 2019. For the full year, net loss reported to INR31.27 crore in the year ended March 2020 as against net profit of INR21.17 crore during the previous year ended March 2019. Sales declined 3.42% to INR771.87 crore in the year ended March 2020 as against INR799.18 crore during the previous year ended March 2019.

SBI to institute work-from-anywhere infrastructure, hopes to save INR1,000 crore

Amid COVID-19 induced disruption, the country's largest lender State Bank of India will institute work-from-anywhere infrastructure and expects to save INR1,000 crore from this measure. The focus going forward will be on cost reduction, rationalization and reskilling of workforce, improving staff productivity and redeployment of workforce from admin offices to sales roles. Following global best practices, the bank will institute work from anywhere (WFA) infrastructure to facilitate work from any location, while taking care of social aspects of work-life balance. The measure is expected to save INR1,000 crore through cost optimization and will be a key component of our business continuity during times of COVID-19.

Piyush Goyal asks industry to setup semi-conductor fabrication plant soon in India

Piyush Goyal said the government is mapping the entire land bank available for manufacturing and urged industry to come up with a semi-conductor fabrication plant soon terming it a “missing piece” in India’s manufacturing. We are mapping the entire land bank available for manufacturing. We need to have a fab coming to India quickly now. That is a missing piece. The minister asked the industry to identify such units which can be moved to India from other countries where they are not viable, and look at clusters where an ecosystem can be created where all clearances are online. also the televisions, air conditioners and closed circuit televisions have been identified as certain sectors where the level of indigenization can increase in the country.

Pharma major Cipla gets USFDA nod for rare genetic condition treatment drug

Cipla has received final approval from the United States Food and Drug Administration (USFDA) for Icatibant Injectable, indicated for treatment of acute attacks of hereditary angioedema - a rare genetic condition - in adults. Cipla's Icatibant injectable pre-filled syringe in the strength of 30mg/3mL is generic version of Shire's Firazyr. It has received final approval for its abbreviated new drug application for Icatibant Injectable 30mg/3mL from the United States Food and Drug Administration. Quoting IQVIA (IMS Health) data, Cipla said Firazyr and its generic equivalents had US sales of approximately USD 270 million for the 12-month period ending May 2020.

Reliance Jio grows user base in March, while Airtel, Voda Idea lose due to lockdown pangs

Reliance Jio Infocomm outgunned its two older incumbent carriers, adding 4.68 million mobile phone users in March 2020, taking its subscriber count well past 387 million, signalling that consumers had taken in their stride the steep tariff hikes the telecom market leader took last December. Bharti Airtel and Vodafone Idea, by contrast, lost 1.26 million and 6.35 million customers respectively in March, in the aftermath of the December 2019 hikes and initial lockdown pangs in late March. Last December, Airtel, VIL and Jio had increased bundled prepaid tariffs for the first time in 3 years by around 14-33%. Data collated by the telecom regulator showed India's mobile user base fell by 2.84 million to nearly 1.158 billion in March. Jio’s March user base swelled to 387.51 million, while Airtel’s and VIL’s fell to 327.81 million and 319.16 million.

Analyst Certification:

We /I, Deepankar Saha & Jaydeb Dey Research Analyst(s) of SMIFS Limited (in short "SMIFS / the Company"), authors and the names subscribed to this Research Report, hereby certify that all of the views expressed in this Research Report accurately reflect our views about the subject issuer(s) or securities and distributed as per SEBI (Research Analysts) Regulations 2014. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this Research Report. It is also confirmed that We/I, the above mentioned Research Analyst(s) of this Research Report have not received any compensation from the subject companies mentioned in the Research Report in the preceding twelve months and do not serve as an officer, director or employee of the subject companies mentioned in the Research Report.

Terms & Conditions and Other Disclosures:

SMIFS Limited is engaged in the business of Stock Broking, Depository Services, Portfolio Management and Distribution of Financial Products. SMIFS Limited is registered as Research Analyst Entity with Securities & Exchange Board of India (SEBI) with Registration Number – INH300001474.

SMIFS and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Research Analysts. SMIFS generally prohibits its analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

The information and opinions in this Research Report have been prepared by SMIFS and are subject to change without any notice. The Research Report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of SMIFS Limited. While we would endeavor to update the information herein on a reasonable basis, SMIFS is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent SMIFS from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or policies of SMIFS, in circumstances where SMIFS might be acting in an advisory capacity to this company, or in certain other circumstances.

This Research Report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This Research Report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Securities as defined in clause (h) of section 2 of the Securities Contract Act, 1956, includes Financial Instruments, Currency and Commodity Derivatives. Though disseminated to all the customers simultaneously, not all customers may receive this Research Report at the same time. SMIFS will not treat recipients as customers by virtue of their receiving this Research Report. Nothing in this Research Report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this Research Report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. SMIFS accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this Research Report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. The information given in this report is as of date of this report and there can be no assurance that future results or events will be consistent with this information. The information provided in this report remains, unless otherwise stated, the copyright of SMIFS. All layout, design, original artwork, concepts and intellectual Properties remains the property and copyright of SMIFS and may not be used in any form or for any purpose whatsoever by any party without the express written permission of the SMIFS.

SMIFS shall not be liable for any delay or any other interruption which may occur in presenting the data due to any reason including network (Internet) reasons or snags in the system, breakdown of the system or any other equipment, server breakdown, maintenance shutdown, breakdown of communication services or inability of SMIFS to present the data. In no event shall SMIFS be liable for any damages, including without limitation direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by the SMIFS through this report.

Participants in foreign exchange transactions may incur risks arising from several factors, including the following: (a) Exchange Rates can be volatile and are subject to large fluctuations; (b) the value of currencies may be affected by numerous market factors, including world and notional economic, political and regulatory events, events in Equity & Debt Markets and changes in interest rates; and (c) Currencies may be subject to devaluation or government imposed Exchange Controls which could affect the value of the Currency. Investors in securities such as Currency Derivatives, whose values are affected by the currency of an underlying security, effectively assume currency risk.

Since associates of SMIFS are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this Research Report.

SMIFS and its Associates, Officers, Directors, Employees, Research Analysts including their relatives worldwide may: (i) from time to time may have long or short positions in, and buy or sell the Securities, mentioned herein or (ii) be engaged in any other transaction involving such Securities and earn brokerage or other compensation or act as a market maker in the Financial Instruments of the Subject Company/ companies mentioned herein or act as an Advisor or Lender/Borrower to such Companies or have other potential/material Conflict of Interest with respect to any recommendation and related information and opinions at the time of the publication of the Research Report. Or at the time of Public Appearance. SMIFS does not have proprietary trades but may at a future date, may opt for the same with prior intimation to Clients/ Investors and extant Authorities where it may have proprietary long/ short position in the above Scrip(s) and therefore should be considered as interested. The views provided herein are general in nature and do not consider Risk Appetite or Investment Objective of any particular Investor; Clients/ Readers/ Subscribers of this Research Report are requested to take independent professional advice before investing. The information provided herein should not be construed as invitation or solicitation to do business with SMIFS.

SMIFS or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the Research Report as of the last day of the month preceding the publication of the Research Report.

SMIFS encourages independence in Research Report preparation and strives to minimize conflict in preparation of Research Report. Accordingly, neither SMIFS and their Associates nor the Research Analysts and their relatives have any material conflict of interest at the time of publication of this Research Report or at the time of the Public Appearance, if any.

SMIFS or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

SMIFS or its associates might have received any compensation from the companies mentioned in the Research Report during the period preceding twelve months from the date of this Research Report for services in respect of managing or co-managing public offerings, corporate finance, investment banking, brokerage services or other advisory service in a merger or specific transaction from the subject company.

SMIFS or its associates might have received any compensation for products or services other than investment banking or brokerage services from the subject companies mentioned in the Research Report in the past twelve months.

SMIFS or its associates or its Research Analysts did not receive any compensation or other benefits whatsoever from the subject companies mentioned in the Research Report or third party in connection with preparation of the Research Report.

Compensation of Research Analysts is not based on any specific Investment Banking or Brokerage Service Transactions.

The Research Analysts might have served as an officer, director or employee of the subject company.

Neither the Research Analysts nor SMIFS have been engaged in market making activity for the companies mentioned in the Research Report.

SMIFS may have issued other Research Reports that are inconsistent with and reach different conclusion from the information presented in this Research Report.

A graph of daily closing prices of the securities/commodities is also available at www.nseindia.com and/or www.bseindia.com, www.mcxindia.com and/or www.icex.com.

SMIFS submit' s that no material disciplinary action has been taken on the Company by any Regulatory Authority impacting Equity Research Analysis activities in last 3 years.

This Research Report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SMIFS and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

For queries related to compliance of the report, please contact: -

Sudipto Datta, Compliance Officer

SMIFS Limited.

Vaibhav, 4 Lee Road, Kolkata 700020, West Bengal, India.

Contact No.: +91 33 4011 5414 /91 33 6634 5414

Email Id.: compliance@smifs.com

Website: www.smifs.com